Financial Performance & Growth - Q2 2025 revenue reached $725 million, a 3% increase compared to Q2 2024[5] - Adjusted EBITDA for Q2 2025 was $184 million, up 13% from Q2 2024[5] - Adjusted EPS for Q2 2025 increased by 56% to $025, compared to $016 in Q2 2024[5] - The company is increasing its 2025 adjusted EBITDA guidance range to $665 million - $685 million[5] - Net revenues are projected to be between $30 billion and $31 billion in 2025, representing a 7% to 11% increase[11] Segment Performance - Specialty segment revenue increased by 13% in the first half of 2025[5] - Affordable Medicines segment revenue increased by 4% in the first half of 2025[5] - AvKARE segment revenue increased by 1% in the first half of 2025[5] - AvKARE revenue reached $663 million in 2024, with a 23% compound annual growth rate (CAGR) from 2020 to 2024, and is projected to exceed $900 million by 2027[24] Product & Pipeline Development - CREXONT is on track to achieve peak U S sales of $300 million to $500 million[39] - The company expects to file a Biologics License Application (BLA) for an omalizumab biosimilar (bXOLAIR) in Q4[5] - The company launched 15 new products in the Affordable Medicines portfolio year-to-date[5]

‒ ‒ Adjusted EBITDA of $184 million; Adjusted Diluted EPS of $0.25 ‒ ‒ Raising 2025 Full Year Guidance ‒ ‒ Full Debt Refinancing Reduces Interest Cost and Extends Maturities to 2032 ‒ BRIDGEWATER, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced its results for the second quarter ended June 30, 2025. "Amneal delivered another quarter of solid growth, strong profitability, and we are pleased to raise our full year 2025 guidance. T ...

Core Insights - Amneal Pharmaceuticals reported preliminary financial results for Q2 2025, indicating robust growth and expectations to meet or exceed full-year guidance [1][3] - The company received FDA approval for Brekiya® autoinjector for migraine treatment and noted strong uptake of CREXONT® [3] - Amneal anticipates a BLA submission for a proposed biosimilar to XOLAIR® in Q4 2025, highlighting a strong pipeline for future growth [3] Financial Performance - Net revenue is projected to be between $720 million and $730 million, reflecting an approximate 3% increase compared to Q2 2024 [7] - Income before income taxes is expected to range from $45 million to $56 million, a significant increase from $20 million in the same period of 2024 [7] - Adjusted EBITDA is projected to be between $180 million and $185 million, marking an approximate 13% increase from Q2 2024 [7] Leverage Metrics - Gross leverage decreased to 3.8x as of June 30, 2025, down from 4.1x as of December 31, 2024 [7] - Net leverage also decreased to 3.7x as of June 30, 2025, compared to 3.9x at the end of 2024, attributed to higher profitability and continued debt reduction [7]

Financial Performance & Growth - Amneal Pharmaceuticals is entering a new era of growth as a global biopharmaceutical company[9] - The company projects net revenues of $3.0 - $3.1 billion for 2025, reflecting a growth of 7% to 11%[11] - Adjusted EBITDA is guided at $650 million - $675 million for 2025, indicating a growth of 4% to 8%[11] - The company's net leverage stands at 3.9x as of Q1 2025, with expectations to reduce it to less than 3x in the coming years[11, 50] Business Diversification & Pipeline - Oral solid generics are decreasing as a percentage of total revenue, from 53% in 2019 to 23%[11] - The pipeline is shifting towards non-oral solids, with 96% of pipeline products being non-oral solids[11, 44] - The company has 3 commercial biosimilars and 5 biosimilars in the pipeline[11] Strategic Initiatives & Product Portfolio - Specialty business revenue reached $449 million in the last twelve months of Q1 2025, growing +11% compared to the prior year period[26] - CREXONT for Parkinson's Disease is expected to achieve $300-500 million in U S peak sales[29] - AvKARE segment is experiencing double-digit growth, aiming for $900 million+ revenue by 2027[16]

Earnings Call Q1 2025 May 2, 2025 1 Cautionary statement on forward looking statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; ex ...

Q4 2024 Earnings Call Q4 2024 earnings call Agenda 1 Strategy & Business Update Chirag and Chintu Patel, Co-founders and Co-CEOs 2 Financial Results Tasos Konidaris, EVP & CFO 3 Q&A Chirag Patel, Co-CEO and President Joe Renda, SVP - Specialty 3 Cautionary statement on forward looking statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking ...